Skip to main content
HUM logo

Humana Inc. (HUM) Stock: Price, Forecast & Analyst Target

Humana Inc. (HUM) — MoonshotScore 79/100 (Strong band), calculated Nov 18, 2026. Price $380.00 (-1.50%), as of the Nov 19, 2026 trading session; market cap $45.6B. Expected results Feb 10, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$380.00 −$5.78 (-1.50%) Market Cap $45.6B

Humana Inc. · HUM · NYSE · Healthcare · Medical - Healthcare Plans

Research dated 2026-09-12: Humana combines health-plan underwriting with CenterWell pharmacy, provider-network and home-based care services, selling coverage directly while also serving government programs, employers and outside clients. The case depends on whether Medicare Advantage bid choices and membership mix can restore durable margins without sacrificing the revenue base that supports Humana’s care-delivery network.

Price as of Nov 19, 2026

Key Statistics

79 of 100

MoonshotScore v2 · Humana (HUM)

Strong
Business Quality Solid (74)
Financial Safety Okay (52)
Valuation Fair (77)
Growth Durability Flat (51)
Momentum Surging (95)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 7 of the last 8 reports
  • expected results Feb 10, 2027
  • Altman Z 4.78 · Piotroski F 8

Helping: business quality, an attractive price, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for HUM (57 recorded, newest six shown)
RecordedScoreBand
76Strong
77Strong
76Strong
76Strong
79Strong
79Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$380.00
Change on the day-1.50%
52-week range$163.11–$462.87
Market capitalisation$45.6B—
Price / earnings (trailing)42.72
Shares traded on the day1.94M
Beta (volatility vs the S&P 500)0.74

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $165, high $450, latest $380. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $450 $165 high $450 Feb 11, 2026 · Earnings results · reported above the recorded estimate · close $1841Apr 29, 2026 · Earnings results · reported above the recorded estimate · close $2342Jul 29, 2026 · Earnings results · reported above the recorded estimate · close $3643Nov 6, 2026 · Earnings results · reported above the recorded estimate · close $4344 Oct 17, 2025 Nov 19, 2026 · $380 $275Oct 17, 2025$278Oct 31, 2025$237Nov 14, 2025$246Nov 28, 2025$268Dec 12, 2025$259Dec 26, 2025$277Jan 9, 2026$267Jan 23, 2026$194Feb 6, 2026$190Feb 20, 2026$179Mar 6, 2026$170Mar 20, 2026$178Apr 2, 2026$205Apr 17, 2026$234May 1, 2026$305May 15, 2026$305May 29, 2026$379Jun 12, 2026$384Jun 26, 2026$392Jul 10, 2026$389Jul 24, 2026$385Aug 7, 2026$379Aug 21, 2026$402Sep 4, 2026$386Sep 18, 2026$388Oct 2, 2026$413Oct 16, 2026$415Oct 30, 2026$450Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Humana (HUM): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Moderate
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Unfavorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Weak
ROE Neutral
Gross Margin Weak

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Simons-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Humana (HUM), and what does it report?

Short answer · as of

Humana is primarily an insurer, but premium revenue is only part of the operating picture.

Its Insurance segment covers individual medical and supplemental plans, state-sponsored benefits, employer coverage, administrative services and military health support, while CenterWell supplies pharmacy management, provider-network services and home-based care to Humana members and external customers.

Reported revenue therefore measures both health-plan activity and care-service activity. Insurance remains the much larger segment, so consolidated growth can coexist with weak earnings when the spread between plan revenue and medical and operating costs narrows; CenterWell adds a service platform, but does not displace underwriting as the dominant economic engine.

2 · Latest results

What do the latest results show for Humana (HUM)?

The latest period extended a sharp revenue advance and remained profitable, but net income, operating income and gross profit all eased from the preceding period. That combination points to continuing volume or premium expansion alongside less favorable profit conversion, rather than a simple contraction in demand.

Reported revenue and earnings came in above expectations, continuing a run in which earnings repeatedly cleared estimates even when statutory results included period-end losses. Management is linking future margin progress to Medicare Advantage bids and to the eventual size and composition of membership; that is an outlook, not yet an explanation proven by the reported margin series.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$41.16B Nov 6, 2026
Latest report · revenue estimate
$40.87B Nov 6, 2026
Latest report · revenue vs estimate
Above estimate Nov 6, 2026
Latest report · EPS vs estimate
Above estimate Nov 6, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 6, 2026$41.16B$40.87B−$0.7000−$1.0000
Jul 29, 2026$40.87B$40.58B$7.6100$7.2700
Apr 29, 2026$39.65B$39.37B$10.3100$10.2400
Feb 11, 2026$32.52B$32.04B−$3.9600−$4.0000
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$32.65B$195M$1.61 (diluted)
Q4 FY2025$32.52B-$796M—
Q1 FY2026$39.65B$1.19B$9.83 (diluted)
Q2 FY2026$40.87B$694M$5.73 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Humana (HUM)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Humana’s cash and short-term investments exceed total debt, leaving a substantial net cash position on the stated liquidity basis. The balance is also far above its recent level, while the quality and distress screens remain constructive.

Cash generation is much less settled than the balance-sheet snapshot suggests. Operating cash flow has swung sharply between inflows and outflows, the latest period was negative, and trailing free-cash-flow yield was below zero; meanwhile, thin net and operating margins leave earnings highly sensitive to medical-cost pressure or bid decisions that fail to price the enrolled population adequately.

4 · What to check next?

What should you watch next at Humana (HUM)?

Short answer · as of

The next earnings report is expected on Feb 10, 2027.

Watch whether revenue can hold near its recently elevated run rate while operating profit and cash flow recover together. Revenue growth without better conversion would reinforce the concern that Humana is adding premium or service volume faster than it is rebuilding economics.

The approaching earnings release carries an expectation of a loss despite roughly stable revenue, making the mix of membership and the profitability of that book more informative than the top line alone. Beyond that release, progress should appear through wider margins and steadier cash generation before management’s Medicare Advantage bid strategy can be treated as delivered.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Humana compare with its peers?

Short answer

Humana's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Humana differs from a health plan whose economics end with collecting premiums and paying claims. CenterWell places pharmacy, provider-network and home-based care inside the same corporate system, and those services can also serve outside clients.

That structure creates more ways to participate in member care, but it does not make Humana a broadly diversified healthcare conglomerate: Insurance still contributes the dominant share of segment revenue. Compared with more balanced managed-care peers, Humana’s results remain especially exposed to how Medicare Advantage bids translate into membership composition and underwriting margin.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Oscar Health, Inc. (OSCR) Same industry, near in market value$26.17 Nov 19, 2026$8.13B97 5-pillar Nov 18, 2026
BeOne Medicines Ltd. (ONC) Named competitor$403.60 Nov 18, 2026$46.1B96 5-pillar Nov 18, 2026
Clover Health Investments, Corp. (CLOV) Same industry, near in market value$3.77 Nov 19, 2026$2.02B94 5-pillar Nov 18, 2026
Centene Corporation (CNC) Same industry, near in market value$65.62 Nov 19, 2026$32.5B91 5-pillar Nov 18, 2026
Elevance Health Inc. (ELV) Same industry, near in market value$390.16 Nov 19, 2026$84.3B88 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Named competitor$175.34 Nov 19, 2026$49.4B83 5-pillar Nov 18, 2026
CVS Health Corporation (CVS) Same industry, near in market value$80.06 Nov 19, 2026$102B81 5-pillar Nov 18, 2026
Alcon Inc. (ALC) Named competitor$74.52 Nov 19, 2026$35.8B80 5-pillar Nov 18, 2026
Humana (HUM) — this page$380.00$45.6B79
Cigna Corporation (CI) Same industry, near in market value$273.09 Nov 19, 2026$72.0B78 5-pillar Nov 18, 2026
UnitedHealth Group Incorporated (UNH) Same industry, near in market value$349.91 Nov 18, 2026$314B76 5-pillar Nov 18, 2026
Haleon plc (HLN) Named competitor$9.08 Nov 18, 2026$39.8B75 5-pillar Nov 18, 2026
Alignment Healthcare, Inc. (ALHC) Same industry, near in market value$6.72 Nov 18, 2026$1.41B73 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$300.00 – $596.00
Consensus target
$483.74
Median target
$495.00

Consensus record · Captured .

Measured against a quoted price of $380.00 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026

Transactions
9
Identified insiders
7
Purchases
0
Sales
2
Other transactions
7

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held HUM in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 20260.56%$24.89MNew position

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

HUM Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

How do Medicare Advantage bids affect Humana’s margins?

Bid choices shape the benefits, pricing and membership Humana attracts, so they influence whether plan revenue adequately covers medical and operating costs. Management expects its bidding approach to advance margin recovery, with actual results dependent on membership size and composition.

What does CenterWell contribute to Humana beyond insurance?

CenterWell provides pharmacy management, provider-network support and home-based care for Humana plan members and external clients. It broadens Humana’s participation in care delivery, although Insurance remains the larger reported revenue engine.

Why can Humana’s revenue rise while its profit weakens?

Premium and service volume can expand even when medical and operating costs absorb more of the revenue. Humana’s recent annual and quarterly record shows exactly that tension: a larger top line has not produced a comparable improvement in net results or margins.

How does Humana’s government business differ from its employer coverage?

Government-linked operations include Medicare-related prescription support, state Medicaid and long-term-care arrangements, and military health services. Employer offerings include insured medical and specialty benefits as well as administrative-services arrangements, giving Humana different revenue and risk relationships across customer groups.

What is the HUM stock price today?

The last price recorded for Humana Inc. (HUM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the HUM price target?

The analyst consensus price target for Humana Inc. (HUM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 34 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Sector / industry (provider taxonomy); Revenue by segment; Management outlook — dated call excerpts
  • 1. What is Humana (HUM), and what does it report?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set
  • 2. What do the latest results show for Humana (HUM)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Most recent periodic reports; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Humana (HUM)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens
  • 4. What should you watch next at Humana (HUM)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Recent SEC filings
  • 5. How does Humana compare with its peers?: Business description; Revenue by segment; Management outlook — dated call excerpts; Trailing twelve-month ratio set
  • FAQ: How do Medicare Advantage bids affect Humana’s margins?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • FAQ: What does CenterWell contribute to Humana beyond insurance?: Business description; Revenue by segment
  • FAQ: Why can Humana’s revenue rise while its profit weakens?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • FAQ: How does Humana’s government business differ from its employer coverage?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.